Leqvio vs Lisinopril: Switching Between Them

Why These Two Drugs Are Not Direct Substitutes

Inclisiran and lisinopril act on entirely separate pathways. Comparing them requires understanding that cardiometabolic risk is not a single dial you turn with one medication. It is a set of independent variables, each demanding its own intervention.

Inclisiran (brand name Leqvio) is a small interfering RNA that silences the gene encoding PCSK9 in hepatocytes. With less PCSK9 protein available to degrade LDL receptors on liver cell surfaces, more receptors recycle back to capture circulating LDL particles. The net effect is a sustained, potent reduction in LDL cholesterol 1. The pooled ORION-10 and ORION-11 trials (N=3,178) demonstrated a time-averaged placebo-adjusted LDL-C reduction of 50.5% over 18 months with just three injections per year during the maintenance phase 1.

Lisinopril, by contrast, is an angiotensin-converting enzyme (ACE) inhibitor. It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium retention. Its primary measurable outcome is lower blood pressure, though ACE inhibitors also confer renal protection in diabetic nephropathy and reduce mortality in heart failure with reduced ejection fraction 2. In the ALLHAT trial (N=33,357), lisinopril performed comparably to chlorthalidone and amlodipine on the primary composite of fatal coronary heart disease and nonfatal myocardial infarction, although it showed a higher 6-year rate of stroke (6.3% vs. 5.6% for chlorthalidone; RR 1.15) and combined cardiovascular disease events 2.

Dropping one of these drugs to start the other means leaving either LDL-C or blood pressure unmanaged. That is not a switch. That is a gap.

When Clinicians Discuss "Switching" and What They Actually Mean

The phrase "switching from Leqvio to lisinopril" typically surfaces in three clinical scenarios, none of which involve a true 1:1 drug substitution.

Scenario 1: Formulary or cost-driven medication changes. A patient on inclisiran loses insurance coverage for the drug. The prescriber may add or intensify statin therapy and an ACE inhibitor to address residual cardiovascular risk more broadly, but the LDL-lowering gap left by removing inclisiran cannot be filled by lisinopril. The appropriate replacement for inclisiran's LDL-C effect would be a PCSK9 monoclonal antibody (evolocumab or alirocumab), bempedoic acid, or high-intensity statin optimization 3.

Scenario 2: Reassessing a regimen after new diagnoses. A patient initially prescribed inclisiran for isolated hypercholesterolemia later develops hypertension. Lisinopril gets added to the regimen. Neither drug replaces the other. The 2019 ACC/AHA guideline on primary prevention of cardiovascular disease recommends treating each risk factor to its respective target 3.

Scenario 3: Simplification of polypharmacy. In older adults with high pill burden, a clinician may deprioritize one medication class. If blood pressure is well-controlled and LDL remains above the treatment threshold, keeping inclisiran (which requires only two injections per year after loading) while discontinuing lisinopril could reduce daily pill count. The reverse decision would be appropriate if LDL-C is at goal but blood pressure is not.

Mechanism of Action: PCSK9 Silencing vs. ACE Inhibition

Understanding why these drugs cannot substitute for each other requires a closer look at their molecular targets.

Inclisiran is a double-stranded siRNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it specifically to hepatocyte asialoglycoprotein receptors. Once internalized, the antisense strand loads into the RNA-induced silencing complex (RISC) and catalytically degrades PCSK9 mRNA. Because RISC is not consumed in the process, a single dose provides months of gene silencing 4. This translates to the durable LDL-C lowering observed in ORION trials without daily dosing.

Lisinopril competitively inhibits ACE, the zinc metallopeptidase that cleaves angiotensin I into the potent vasoconstrictor angiotensin II. The downstream effects include reduced aldosterone, decreased sodium reabsorption, and lower peripheral vascular resistance. ACE also degrades bradykinin, so ACE inhibition raises bradykinin levels, contributing to vasodilation but also explaining the characteristic dry cough seen in 5% to 20% of patients 5.

These two mechanisms share no overlapping pathway. A patient who stops inclisiran will see LDL-C rise over 3 to 6 months as PCSK9 levels recover. A patient who stops lisinopril will see blood pressure climb within days. The timelines are different, the risks are different, and the monitoring required during any transition is different.

Clinical Trial Data: What Each Drug Has Proven

No head-to-head trial between inclisiran and lisinopril exists, and designing one would be scientifically incoherent given their different targets. The evidence base for each drug stands independently.

Inclisiran: ORION Program

In ORION-10 (patients with ASCVD, N=1,561) and ORION-11 (patients with ASCVD or ASCVD risk equivalents, N=1,617), inclisiran 284 mg given at day 1, day 90, and every 6 months thereafter reduced LDL-C by 52.3% (ORION-10) and 49.9% (ORION-11) versus placebo at day 510 1. The most common adverse event was injection-site reaction, occurring in 5% of inclisiran patients versus 0.7% on placebo. Serious adverse events were balanced between groups.

Dr. Kausik Ray, lead investigator of the ORION program, stated: "Inclisiran offers a fundamentally different approach to cholesterol management by addressing the root cause of LDL receptor recycling with just two injections per year after the initial loading period" 1.

The ORION-4 cardiovascular outcomes trial (N=15,968) is evaluating whether inclisiran's LDL-C reduction translates to reductions in major adverse cardiovascular events. Results are expected to report between 2026 and 2027 6.

Lisinopril: ALLHAT and Beyond

ALLHAT remains the largest antihypertensive trial ever conducted. Among 33,357 high-risk hypertensive patients randomized to chlorthalidone, amlodipine, or lisinopril, the lisinopril arm showed equivalent primary endpoint rates (fatal CHD or nonfatal MI) to chlorthalidone (RR 0.99 to 95% CI 0.91 to 1.08) 2. Blood pressure control was modestly worse with lisinopril, particularly in Black participants, and the lisinopril arm had higher rates of stroke and combined CVD.

The 2017 ACC/AHA blood pressure guideline positions ACE inhibitors as first-line therapy for hypertension in patients with compelling indications including diabetes, chronic kidney disease, heart failure with reduced ejection fraction, and post-myocardial infarction 7.

Safety Profiles and Monitoring During Transitions

If a prescriber adjusts a regimen that includes either drug, monitoring protocols differ substantially.

Stopping inclisiran. Because the drug's effect wanes gradually as PCSK9 mRNA silencing fades, LDL-C will rise over the 3 to 6 months following the last injection. Lipid panels should be repeated at 3 months and 6 months post-discontinuation. If the patient is transitioning to a PCSK9 monoclonal antibody, the first injection of evolocumab or alirocumab can be given at the time the next inclisiran dose would have been due 8.

Stopping lisinopril. ACE inhibitor withdrawal produces a rebound in angiotensin II within 24 to 48 hours. Blood pressure should be monitored daily for the first week. If switching to an ARB (a common transition for patients with ACE inhibitor cough), the ARB can typically be started the day after the last lisinopril dose. Potassium and creatinine should be checked within 1 to 2 weeks of any change in renin-angiotensin-aldosterone system (RAAS) therapy 7.

Adding inclisiran to a lisinopril regimen. No dose adjustment of either drug is needed. Inclisiran does not interact with CYP450 enzymes, and it is not a substrate for common drug transporters. Co-prescription is pharmacologically uncomplicated 1.

Adding lisinopril to an inclisiran regimen. Standard lisinopril initiation applies: start at 5 to 10 mg daily, titrate every 2 to 4 weeks, monitor renal function and potassium at baseline and after each titration.

Cost, Access, and Practical Switching Barriers

The cost disparity between these medications is enormous, and it drives many of the "switching" conversations patients initiate.

Generic lisinopril costs between $4 and $15 per month at most pharmacies. It is on the $4 generic list at multiple national chains. No prior authorization is required by any major insurer 9.

Inclisiran carries a wholesale acquisition cost of approximately $3,250 per injection. With two maintenance doses per year, the annual cost reaches $6,500 before insurance. Medicare Part B covers inclisiran as a physician-administered injection (it is given in-office, not self-injected), and Novartis offers a patient assistance program for eligible commercially insured and uninsured patients 9.

The ACC's 2022 Expert Consensus Decision Pathway on the role of nonstatin therapies recommends considering PCSK9 inhibitors (including inclisiran) for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy. The threshold drops to 55 mg/dL for very high-risk ASCVD patients 8.

Dr. Donald Lloyd-Jones, former president of the American Heart Association, has noted: "The biggest barrier to cardiovascular risk reduction is not the pharmacology. It is the implementation gap between what guidelines recommend and what patients actually receive" 3.

Who Might Need Both Drugs Simultaneously

The patient most likely to benefit from both inclisiran and lisinopril has established atherosclerotic cardiovascular disease with co-existing hypertension, a profile that describes a large proportion of the ASCVD population.

Data from the National Health and Nutrition Examination Survey (NHANES) 2017 to 2020 show that among adults with self-reported cardiovascular disease, 74.5% also carried a hypertension diagnosis 10. For these patients, addressing only LDL-C or only blood pressure leaves significant residual risk on the table.

A typical regimen for a 62-year-old with prior MI, LDL-C of 85 mg/dL on atorvastatin 80 mg, and blood pressure of 142/88 mmHg might include: atorvastatin 80 mg daily, inclisiran 284 mg every 6 months (to push LDL-C below the 55 mg/dL very-high-risk threshold), lisinopril 20 mg daily (for BP target <130/80 per ACC/AHA guidelines), and aspirin 81 mg daily. None of these agents replaces another. Each addresses a distinct mechanistic target.

How to Talk to Your Prescriber About Regimen Changes

Patients searching for information about "switching" between these drugs often want to reduce the number of medications they take, manage side effects, or lower out-of-pocket costs. Three questions to bring to your prescriber:

1. "Which risk factor is my biggest threat right now?" If your LDL-C is 45 mg/dL but your blood pressure is 155/95, lisinopril (or another antihypertensive) is doing more acute work than inclisiran at this moment.

2. "Can I pause one drug safely while keeping the other?" The answer depends on your baseline risk. A patient 2 years post-MI with LDL-C of 130 mg/dL off lipid therapy cannot safely stop inclisiran without a replacement LDL-lowering strategy. A patient with stage 1 hypertension and no end-organ damage may be able to trial lifestyle modifications before restarting lisinopril.

3. "What monitoring do I need if we change anything?" Expect a lipid panel 3 months after stopping inclisiran and a blood pressure recheck within 1 week of stopping lisinopril. Creatinine and potassium labs apply whenever RAAS therapy changes.

The Evidence Gap: What We Still Do Not Know

Several questions remain unanswered in the relationship between PCSK9-targeted therapy and ACE inhibition.

First, whether inclisiran's LDL-C reduction translates to hard cardiovascular outcome reductions awaits the ORION-4 results. The PCSK9 monoclonal antibodies (evolocumab in FOURIER, alirocumab in ODYSSEY OUTCOMES) have demonstrated MACE reductions of 15% to 20% 6, and the expectation is that inclisiran will show similar benefit given the same LDL-C-lowering magnitude. But expectation is not evidence.

Second, no trial has examined whether combined aggressive LDL-C lowering (via statin plus inclisiran) and aggressive BP lowering (via ACE inhibitor plus additional agents) produces additive, synergistic, or merely parallel risk reduction. The HOPE-3 trial (N=12,705) tested rosuvastatin and candesartan/hydrochlorothiazide in intermediate-risk patients and found that combined therapy reduced major cardiovascular events by 29% compared to dual placebo, but the cholesterol-lowering component drove most of the benefit in patients without baseline hypertension 11.

Third, real-world adherence data for inclisiran are still maturing. The theoretical advantage of twice-yearly dosing over daily pills is compelling, but it depends on patients returning for in-office injections every 6 months. Early post-marketing data suggest adherence rates above 85% at 18 months, though longer follow-up in diverse populations is needed 1.

Patients taking lisinopril 10 to 20 mg daily who also receive inclisiran 284 mg every 6 months need no dose modification of either drug, but they should have LDL-C checked at least annually and blood pressure assessed at every clinic visit per current ACC/AHA recommendations 7.